{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:07:21Z","timestamp":1788286041990,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-12301-w","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:44:44Z","timestamp":1767714284000},"page":"5068-5081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-8369","authenticated-orcid":false,"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent P.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Kostakoglu Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Phin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie S.","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minas P.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"12301_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"12301_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096","journal-title":"JAMA Oncol"},{"key":"12301_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP et al (2021) A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol 206:52\u201361. https:\/\/doi.org\/10.1097\/JU.0000000000001698","journal-title":"J Urol"},{"key":"12301_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/JU.0000000000003598","volume":"210","author":"AB Jani","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA et al (2023) Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). Reply. J Urol 210:411\u2013412. https:\/\/doi.org\/10.1097\/JU.0000000000003598","journal-title":"J Urol"},{"key":"12301_CR5","unstructured":"National Comprehensive Cancer Network (2025) Clinical practice guidelines in oncology. Prostate cancer version 1. Available via https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 2 Jun 2025"},{"key":"12301_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.124.268555","volume":"66","author":"SR Miller","year":"2025","unstructured":"Miller SR, Gonzalez RT, Jackson WC et al (2025) Rates of PSMA PET staging and positivity in newly diagnosed prostate cancer in a national health care system. J Nucl Med 66:75\u201383. https:\/\/doi.org\/10.2967\/jnumed.124.268555","journal-title":"J Nucl Med"},{"key":"12301_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"12301_CR8","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s00330-025-11514-3","volume":"35","author":"S Woo","year":"2025","unstructured":"Woo S, Becker AS, Leithner D et al (2025) PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease. Eur Radiol 35:5337\u20135347. https:\/\/doi.org\/10.1007\/s00330-025-11514-3","journal-title":"Eur Radiol"},{"key":"12301_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS et al (2024) Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging 12:485\u2013500. https:\/\/doi.org\/10.1007\/s40336-024-00631-6","journal-title":"Clin Transl Imaging"},{"key":"12301_CR10","doi-asserted-by":"publisher","first-page":"umae008","DOI":"10.1093\/radadv\/umae008","volume":"1","author":"D Mar","year":"2024","unstructured":"Mar D, Diwanji D, Lowery B et al (2024) Pathologic outcome of incidentally detected tracer-avid lesions in 68Ga-PSMA-11 PET\/CT for prostate cancer. Radiol Adv 1:umae008. https:\/\/doi.org\/10.1093\/radadv\/umae008","journal-title":"Radiol Adv"},{"key":"12301_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-018-0175-3","volume":"18","author":"Z Keidar","year":"2018","unstructured":"Keidar Z, Gill R, Goshen E et al (2018) 68Ga-PSMA PET\/CT in prostate cancer patients\u2014patterns of disease, benign findings and pitfalls. Cancer Imaging 18:39. https:\/\/doi.org\/10.1186\/s40644-018-0175-3","journal-title":"Cancer Imaging"},{"key":"12301_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP et al (2023) Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol 84:491\u2013502. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.008","journal-title":"Eur Urol"},{"key":"12301_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP et al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83:405\u2013412. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002","journal-title":"Eur Urol"},{"key":"12301_CR14","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L et al (2021) E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 48:1626\u20131638. https:\/\/doi.org\/10.1007\/s00259-021-05245-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12301_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.250702","volume":"317","author":"HA Vargas","year":"2025","unstructured":"Vargas HA, Fanti S, Herrmann K et al (2025) PSMA PET\/CT reporting: real-life inconsistencies, heterogeneity, and underutilization of scoring systems and interpretation frameworks. Radiology 317:e250702. https:\/\/doi.org\/10.1148\/radiol.250702","journal-title":"Radiology"},{"key":"12301_CR16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.250701","volume":"317","author":"S Woo","year":"2025","unstructured":"Woo S, Masci B, Rowe SP et al (2025) Navigating the scoring systems and interpretation frameworks of prostate-specific membrane antigen PET. Radiology 317:e250701. https:\/\/doi.org\/10.1148\/radiol.250701","journal-title":"Radiology"},{"key":"12301_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2967\/jnumed.118.217653","volume":"60","author":"Y Yin","year":"2019","unstructured":"Yin Y, Werner RA, Higuchi T et al (2019) Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. J Nucl Med 60:511\u2013516. https:\/\/doi.org\/10.2967\/jnumed.118.217653","journal-title":"J Nucl Med"},{"key":"12301_CR18","doi-asserted-by":"publisher","unstructured":"Woo S, Freedman D, Becker AS et al (2025) Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET\/CT. Abdom Radiol (NY) https:\/\/doi.org\/10.1007\/s00261-025-04948-2","DOI":"10.1007\/s00261-025-04948-2"},{"key":"12301_CR19","doi-asserted-by":"publisher","first-page":"482.e5","DOI":"10.1016\/j.urolonc.2016.05.026","volume":"34","author":"HA Vargas","year":"2016","unstructured":"Vargas HA, Martin-Malburet AG, Takeda T et al (2016) Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng\/ml following prostatectomy: how much information can conventional imaging provide? Urol Oncol 34:482.e5\u2013482.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2016.05.026","journal-title":"Urol Oncol"},{"key":"12301_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.2214\/AJR.15.15761","volume":"206","author":"S Woo","year":"2016","unstructured":"Woo S, Kim SY, Kim SH, Cho JY (2016) JOURNAL CLUB: Identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer. AJR Am J Roentgenol 206:1156\u20131163. https:\/\/doi.org\/10.2214\/AJR.15.15761","journal-title":"AJR Am J Roentgenol"},{"key":"12301_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2024.0013","volume":"57","author":"S Woo","year":"2024","unstructured":"Woo S, Becker AS, Ghafoor S et al (2024) Inguinal lymph node metastases from prostate cancer: clinical, pathology, and multimodality imaging considerations. Radiol Bras 57:e20240013. https:\/\/doi.org\/10.1590\/0100-3984.2024.0013","journal-title":"Radiol Bras"},{"key":"12301_CR22","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1007\/s00330-020-07572-4","volume":"31","author":"FHJ Elsholtz","year":"2021","unstructured":"Elsholtz FHJ, Asbach P, Haas M et al (2021) Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol 31:6116\u20136124. https:\/\/doi.org\/10.1007\/s00330-020-07572-4","journal-title":"Eur Radiol"},{"key":"12301_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N et al (2017) Metastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.033","journal-title":"Eur Urol"},{"key":"12301_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J et al (2020) Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int 126:396\u2013401. https:\/\/doi.org\/10.1111\/bju.15152","journal-title":"BJU Int"},{"key":"12301_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2967\/jnumed.122.264334","volume":"64","author":"TE Phelps","year":"2023","unstructured":"Phelps TE, Harmon SA, Mena E et al (2023) Predicting outcomes of indeterminate bone lesions on 18F-DCFPyL PSMA PET\/CT scans in the setting of high-risk primary or recurrent prostate cancer. J Nucl Med 64:395\u2013401. https:\/\/doi.org\/10.2967\/jnumed.122.264334","journal-title":"J Nucl Med"},{"key":"12301_CR26","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, Thomas PA, Roberts MJ et al (2021) Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging 48:4495\u20134507. https:\/\/doi.org\/10.1007\/s00259-021-05456-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12301_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","journal-title":"Eur Urol"},{"key":"12301_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A Stabile","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E et al (2022) Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol 5:1\u201317. https:\/\/doi.org\/10.1016\/j.euo.2021.08.001","journal-title":"Eur Urol Oncol"},{"key":"12301_CR29","doi-asserted-by":"publisher","first-page":"00482","DOI":"10.1016\/j.eururo.2025.08.005","volume":"S0302-2838","author":"K Herrmann","year":"2025","unstructured":"Herrmann K, Walz J, MacLennan S et al (2025) SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis. Eur Urol S0302-2838:00482\u201300488. https:\/\/doi.org\/10.1016\/j.eururo.2025.08.005","journal-title":"Eur Urol"},{"key":"12301_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00948-1","volume":"12","author":"KH Leung","year":"2022","unstructured":"Leung KH, Rowe SP, Leal JP et al (2022) Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res 12:76. https:\/\/doi.org\/10.1186\/s13550-022-00948-1","journal-title":"EJNMMI Res"},{"key":"12301_CR31","unstructured":"EXINI Diagnostics AB (2022) [aPROMISE X] K220590. Accessed December 6, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K220590"},{"key":"12301_CR32","doi-asserted-by":"publisher","unstructured":"Koehler D, Shenas F, Sauer M et al (2025) PSMA PET evaluation with a deep learning platform compared with a standard image viewer and histopathology. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.125.270242","DOI":"10.2967\/jnumed.125.270242"},{"key":"12301_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.euo.2024.07.007","volume":"8","author":"F Ridouani","year":"2025","unstructured":"Ridouani F, Alberto Vargas H, Holzwanger DJ et al (2025) Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer. Eur Urol Oncol 8:355\u2013363. https:\/\/doi.org\/10.1016\/j.euo.2024.07.007","journal-title":"Eur Urol Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12301-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:26:16Z","timestamp":1779798376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12301-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["12301"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12301-w","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Sungmin Woo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: K.P.F. is a co-investigator on \u201cOptimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy,\u201d but does not receive any salary support and is unrelated to the current work. M.E.M. received honoraria for lectures from Siemens, GE, and BM, but unrelated to the current work. L.K.S. received Honoraria and travel, accommodation, and expenses from Lantheus Medical Imaging and has consulting roles at Roche\/Genentech and Point BioPharma. J.S.W. received funding from EDAP, FocalOne, Uro-1 Medical, ExoDx, and Francis Medical. M.P.E. has received advisory board fees from Merck, Eisai, and Aveo Oncology. D.R.W. has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer, but unrelated to the current work. M.J.Z. has received honoraria for speaking engagements from Elekta and as a consultant for Boston Scientific. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No overlapping study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}